{"id":3029,"date":"2026-08-27T13:26:21","date_gmt":"2026-08-27T12:26:21","guid":{"rendered":"https:\/\/officialcorepeptides.brandloom.net\/en\/?post_type=product&p=3029"},"modified":"2026-08-27T13:26:21","modified_gmt":"2026-08-27T12:26:21","slug":"buy-thymosin-alpha-1-in-switzerland","status":"publish","type":"product","link":"https:\/\/officialcorepeptides.ch\/en\/product\/buy-thymosin-alpha-1-in-switzerland\/","title":{"rendered":"Thymosin Alpha-1 (5MG \/ 10MG)"},"content":{"rendered":"

What Is Thymosin Alpha-1?<\/h2>\n

Thymosin Alpha-1 (T\u03b11), also known as Thymalfasin, is a synthetic 28-amino acid acetylated peptide with the sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH. It replicates the biologically active fragment of prothymosin alpha, a naturally occurring thymic hormone. Researchers first isolated T\u03b11 from calf thymus tissue in 1977 at Abraham White’s laboratory, as reported in the Proceedings of the National Academy of Sciences. For those looking to buy Thymosin Alpha-1 in Switzerland<\/strong>, Core Peptides offers high-quality research-grade material for laboratory applications.<\/p>\n

Thymosin Alpha-1 derives from the larger precursor protein prothymosin alpha and represents the biologically active fragment responsible for the thymus gland’s role in T-cell education and immune regulation. The synthetic version is structurally identical to the endogenous peptide, and manufacturers produce it through solid-phase synthesis. The peptide is commercially available as thymalfasin under the brand name Zadaxin, approved in more than 35 countries for the treatment of chronic hepatitis B. The peptide is identified by CAS number 62304-98-7, with a molecular formula of C129H215N33O55 and a molecular weight of approximately 3,108.3 g\/mol.<\/p>\n

Thymosin Alpha-1 Research Overview<\/h2>\n

Thymosin Alpha-1 has attracted sustained research interest as a well-characterized immunomodulatory peptide with a substantial international clinical literature spanning over four decades. It is approved as Zadaxin in more than 35 countries for chronic hepatitis B, but it is not FDA-approved in the United States. In the US, it holds FDA 503A Category 2 status following the February 2026 reclassification.<\/p>\n

Research interest in Thymosin Alpha-1 centers on its ability to modulate immune function through Toll-like receptor (TLR) signaling, T-cell maturation, and Th1 polarization. Studies have demonstrated that T\u03b11 binds to TLR3, TLR4, and TLR9, activating downstream IRF3 and NF-\u03baB signal pathways. This activation promotes the proliferation and activation of target immune cells. Moreover, TLR2 and TLR7 are also associated with T\u03b11, with TLR2\/NF-\u03baB, TLR2\/p38MAPK, or TLR7\/MyD88 signaling pathways activated to promote cytokine production, enhancing both innate and adaptive immune responses. Consequently, Thymosin Alpha-1 has generated significant interest as a research tool for investigating immunomodulation, T-cell biology, antiviral mechanisms, and infectious disease models.<\/p>\n

When researchers choose to buy Thymosin Alpha-1 in Switzerland<\/strong> for laboratory studies, they gain access to a compound that may help elucidate mechanisms of TLR signaling, T-cell differentiation, and immune regulation at the molecular level.<\/p>\n

How Does Thymosin Alpha-1 Work?<\/h2>\n

Thymosin Alpha-1 exerts its biological effects through multiple interconnected mechanisms involving Toll-like receptor signaling, T-cell maturation, and cytokine modulation. The peptide’s mechanism involves several well-characterized steps.<\/p>\n

Toll-Like Receptor Signaling<\/h3>\n

Thymosin Alpha-1 acts as an immunostimulatory peptide by interacting with various Toll-like receptors (TLRs). Specifically, T\u03b11 can bind to TLR3, TLR4, and TLR9 and activate downstream IRF3 and NF-\u03baB signal pathways, thereby promoting the proliferation and activation of target immune cells. Moreover, TLR2 and TLR7 are also associated with T\u03b11. TLR2\/NF-\u03baB, TLR2\/p38MAPK, or TLR7\/MyD88 signaling pathways are activated by T\u03b11 to promote the production of various cytokines, thereby enhancing the innate and adaptive immune responses. This TLR-mediated mechanism represents the primary molecular pathway through which T\u03b11 exerts its immunomodulatory effects.<\/p>\n

T-Cell Maturation and Th1 Polarization<\/h3>\n

Thymosin Alpha-1 promotes T-lymphocyte maturation and differentiation, regulating the balance between helper and suppressor T-cell subpopulations. The core mechanism of T\u03b11 involves activation of TLR9 signaling on dendritic cells, driving Th1 polarization, T-cell maturation, and coordinated adaptive immune responses. This Th1 polarization is critical for the peptide’s immunomodulatory effects and its role in antiviral research models.<\/p>\n

Natural Killer Cell and Cytokine Modulation<\/h3>\n

T\u03b11 can influence the functions of various immune cells, including T cells, B cells, macrophages, and natural killer (NK) cells. The peptide stimulates NK cell activity and modulates cytokine production by stimulated lymphocytes. These effects contribute to the restoration of immune function in conditions where T-cell function is depressed.<\/p>\n

Direct Cellular Effects<\/h3>\n

Thymosin Alpha-1 is a peptide with a multitude of effects in the organism both from its direct influence on cells, as well as modulation of the immune system. T\u03b11 also displays antiviral and antitumor activities, and has been shown to stimulate endothelial cell migration, angiogenesis, and wound healing.<\/p>\n

Researchers who buy Thymosin Alpha-1 in Switzerland<\/strong> for research purposes can investigate these mechanisms across diverse experimental models of immunology, infectious disease, and antiviral research.<\/p>\n

Why Is Thymosin Alpha-1 Studied?<\/h2>\n

Researchers study Thymosin Alpha-1 primarily for its potential relevance to immunomodulation, T-cell biology, antiviral research, and immune regulation. The peptide’s ability to regulate T-lymphocyte maturation, stimulate NK cell activity, and modulate TLR-mediated signaling makes it a valuable tool for understanding the molecular basis of immune system function and regulation.<\/p>\n

Thymosin Alpha-1 has been extensively studied in the context of viral infectious diseases. T\u03b11 is commonly used as an immune enhancer in viral infectious diseases such as hepatitis B, hepatitis C, and acquired immune deficiency syndrome (AIDS). In a pivotal 1998 randomized controlled trial in 98 hepatitis B patients, T\u03b11 produced a complete virological response in 40.6% of treated patients versus 9.4% in untreated controls. The peptide has been evaluated in multiple Phase 2 and Phase 3 clinical trials for hepatitis B.<\/p>\n

Moreover, researchers study Thymosin Alpha-1 in the context of immunosenescence\u2014the age-related decline in immune function. Preclinical and clinical studies show that T\u03b11 can improve vaccine response in the elderly and mitigate immunosenescence. The peptide has also demonstrated anti-inflammatory and antioxidant properties.<\/p>\n

Recent research has explored Thymosin Alpha-1’s potential in combination with other agents. A 2021 study demonstrated that Thymosin Alpha-1 administration in older patients with severe COVID-19 resulted in more rapid clinical improvement, higher recovery from lymphopenia, faster normalization of inflammatory markers, and halved hospital mortality. However, the 2025 TESTS trial (N=1,089) found no reduction in 28-day sepsis mortality.<\/p>\n

Researchers who buy Thymosin Alpha-1 in Switzerland<\/strong> from Core Peptides can incorporate this peptide into their studies on immunomodulation, T-cell biology, TLR signaling, and infectious disease models.<\/p>\n

Thymosin Alpha-1 Research Areas<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n
Research Area<\/th>\nDescription<\/th>\n<\/tr>\n<\/thead>\n
Immunomodulation<\/strong><\/td>\nInvestigating Thymosin Alpha-1’s effects on T-cell maturation, differentiation, and immune system regulation<\/td>\n<\/tr>\n
TLR Signaling<\/strong><\/td>\nStudying T\u03b11’s binding to TLR3\/4\/9 and activation of IRF3 and NF-\u03baB pathways<\/td>\n<\/tr>\n
T-Cell Biology<\/strong><\/td>\nExamining T\u03b11’s influence on Th1 polarization and T-cell surface marker expression<\/td>\n<\/tr>\n
Antiviral Research<\/strong><\/td>\nExploring T\u03b11’s effects in hepatitis B, hepatitis C, and other viral models<\/td>\n<\/tr>\n
Natural Killer Cell Activity<\/strong><\/td>\nInvestigating T\u03b11’s stimulation of NK cell function and cytotoxic activity<\/td>\n<\/tr>\n
Immunosenescence<\/strong><\/td>\nPreclinical research into T\u03b11’s effects on age-related immune decline and vaccine response<\/td>\n<\/tr>\n
Cytokine Modulation<\/strong><\/td>\nStudying T\u03b11’s effects on pro-inflammatory cytokine production and immune balance<\/td>\n<\/tr>\n
Antitumor Research<\/strong><\/td>\nInvestigating T\u03b11’s antitumor activities and role in immunotherapy research<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Scientific Research on Thymosin Alpha-1<\/h2>\n

Researchers have conducted extensive scientific studies on Thymosin Alpha-1 in both in vitro and in vivo settings, deriving evidence from cell cultures, preclinical models, and clinical research. The peptide has a substantial international clinical literature and has been studied for over four decades.<\/p>\n

In Vitro Evidence<\/h3>\n

In vitro studies have demonstrated that Thymosin Alpha-1 binds to Toll-like receptors TLR3, TLR4, and TLR9, activating downstream IRF3 and NF-\u03baB signal pathways. This activation promotes the proliferation and activation of target immune cells. Research has shown that TLR2 and TLR7 are also associated with T\u03b11, with TLR2\/NF-\u03baB, TLR2\/p38MAPK, or TLR7\/MyD88 signaling pathways activated to promote the production of various cytokines.<\/p>\n

Studies have also investigated T\u03b11’s effects on immune cell subsets. T\u03b11 exhibited direct effects on the proliferation and\/or transcription of activated CD8+ T cells, while minimally changing cancer cell DEGs and immune-related biological processes.<\/p>\n

Preclinical Studies<\/h3>\n

In animal models, Thymosin Alpha-1 administered in vivo strengthens the immune reaction in a whole variety of animal models. The peptide has demonstrated antiviral and antitumor activities, and has been shown to stimulate endothelial cell migration, angiogenesis, and wound healing.<\/p>\n

Research has also explored T\u03b11’s role in modulating the immune system, with studies showing that the peptide influences the functions of immune cells such as T cells, B cells, macrophages, and natural killer cells.<\/p>\n

Human Research<\/h3>\n

Thymosin Alpha-1 has been extensively studied in human clinical research. A pivotal 1998 randomized controlled trial in 98 hepatitis B patients found complete virological response in 40.6% on T\u03b11 versus 9.4% in untreated controls. The peptide has been evaluated in multiple Phase 2 and Phase 3 clinical trials for hepatitis B.<\/p>\n

As of April 2026, thymosin alpha-1 is not FDA-approved in the United States. However, it is approved internationally under the brand name Zadaxin for chronic hepatitis B in more than 35 countries, including China and Italy. In the US, it holds FDA 503A Category 2 status following the February 2026 reclassification, meaning it is available by prescription only through licensed compounding pharmacies.<\/p>\n

Nevertheless, researchers should note that Thymosin Alpha-1 is supplied for laboratory research purposes only. Scientists who buy Thymosin Alpha-1 in Switzerland<\/strong> should remain aware of these evidence considerations.<\/p>\n

Thymosin Alpha-1 Compared With Related Peptides<\/h2>\n\n\n\n\n\n\n\n\n\n
Peptide\/Preparation<\/th>\nRelationship to Thymosin Alpha-1<\/th>\nKey Differences<\/th>\n<\/tr>\n<\/thead>\n
Thymalin<\/strong><\/td>\nBoth are thymic immunomodulators<\/td>\nThymalin is a polypeptide complex (mixture); Thymosin Alpha-1 is a single defined 28-amino acid peptide<\/td>\n<\/tr>\n
Thymogen (Glu-Trp)<\/strong><\/td>\nBoth are thymic peptides<\/td>\nThymogen is a synthetic dipeptide; Thymosin Alpha-1 is a 28-amino acid peptide<\/td>\n<\/tr>\n
Vilon (Lys-Glu)<\/strong><\/td>\nBoth are Khavinson bioregulators<\/td>\nVilon is a dipeptide; Thymosin Alpha-1 is a 28-amino acid peptide with broader immunomodulatory effects<\/td>\n<\/tr>\n
Crystagen (Glu-Asp-Pro)<\/strong><\/td>\nBoth are thymic peptides<\/td>\nCrystagen is a tripeptide targeting thymus-independent immunity; Thymosin Alpha-1 targets TLR signaling and T-cell maturation<\/td>\n<\/tr>\n
Thymosin Beta-4 (TB-500)<\/strong><\/td>\nBoth are thymosin family peptides<\/td>\nThymosin Beta-4 targets actin dynamics and tissue repair; Thymosin Alpha-1 targets immunomodulation and TLR signaling<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Research Applications<\/h2>\n

Researchers utilize Thymosin Alpha-1 in a variety of laboratory research applications, primarily in the fields of immunology, infectious disease, and cellular signaling. Key research applications include:<\/p>\n